BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Dublin, Oct. 17, 2016 -- Research and Markets has announced the addition of the "Central Nervous System Disorders Pipeline Database - 2016 Update" report to their offering.
Central Nervous System Disorders Pipeline Highlights Database - 2016 Update, provides most up-to-date information on key pipeline products in the global Central Nervous System (CNS) disorders Drug market. It covers emerging therapies for CNS indications in active clinical development stages including early and late stage clinical trials. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease. The pipeline data is presented in an excel dashboard with filtering options.
The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
By Indication:
The database presents pipeline by CNS indications. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease.
By Clinical Trial Stages:
The database provides CNS disorders pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The database provides CNS disorders pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.
By Company:
The database provides CNS disorders pipeline products by the company.
SUMMARY:
- CNS disorders Pipeline by Indication
- CNS disorders Pipeline by Clinical Trial Phase
- CNS disorders Pipeline by Drug Mechanism Classes
- CNS disorders Pipeline by Company
For more information about this report visit http://www.researchandmarkets.com/research/68wfzs/central_nervous
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs
